{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:46:20Z","timestamp":1781059580888,"version":"3.54.1"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate\u2013severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with psoriasis for up to 5 years. Methods: This is a retrospective study on a monocentric cohort of patients with psoriasis on secukinumab evaluating the achievement of PASI100, PASI90, and PASI \u2264 3 and DS analysis up to 260 weeks. DS multivariate analysis was carried out considering sex, age, age of onset of the disease, obesity, cardiovascular comorbidities, diabetes, involvement of difficult-to-treat sites, psoriatic arthritis, treatment-na\u00efve status, and mean baseline PASI. Results: At baseline, we evaluated 255 patients on secukinumab. PASI100 was reached by 41.7% and 70.6% of patients at weeks 16 and 260, respectively. PASI90 showed a similar trend with 46.5% of patients achieving it at week 16 and 88.2% at week 260. Non-obese patients showed a faster response than patients with obesity in achieving PASI100, PASI90, and PASI \u2264 3, with significant differences at 28 weeks [55% vs. 40% (p = 0.033), 64% vs. 49% (p = 0.038), and 76% vs. 62% (p = 0.036), respectively]. The estimated DS for secukinumab was 84.3% at 12 and 48% at 60 months. Obesity and smoking habits were associated with a higher risk of discontinuation in multivariate models (HR 1.6 CI 1.05\u20132.45, p = 0.028; HR 1.48 CI 1.01\u20132.17, p = 0.043, respectively). Conclusions: Secukinumab showed effectiveness for up to 5 years of treatment, with a high DS and achievement of PASI100, PASI90, and PASI &lt; 3 at these time points. Only obesity reduced the response and maintenance of DS.<\/jats:p>","DOI":"10.3390\/jpm14070718","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:35:57Z","timestamp":1720006557000},"page":"718","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cariti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Susca","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Siliquini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stroppiana","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Verrone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isotta","family":"Giunipero di Corteranzo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1111\/jdv.17766","article-title":"Comparison of secukinumab and Ixekizumab in psoriasis: A real-life cohort study on the efficacy and drug survival of 445 patients","volume":"36","author":"Cariti","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bugaut, H., and Aractingi, S. (2021). Major Role of the IL17\/23 Axis in Psoriasis Supports the Development of New Targeted Therapies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.621956"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/exd.13284","article-title":"Granzyme A potentiates chemokine production in IL-17-stimulated keratinocytes","volume":"26","author":"Cheuk","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaad.2018.02.040","article-title":"Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis","volume":"79","author":"Lockshin","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3892\/etm.2022.11124","article-title":"Update on the etiopathogenesis of psoriasis (Review)","volume":"23","author":"Branisteanu","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","article-title":"Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study","volume":"21","author":"Kampylafka","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: Results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.31138\/mjr.33.1.150","article-title":"Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNF\u03b1, IL-17, IL-23 or JAK Inhibitors?","volume":"33","author":"Gialouri","year":"2022","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1111\/jdv.18069","article-title":"Real-life comparison of secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis","volume":"36","author":"Avallone","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Avallone, G., Maronese, C.A., Murgia, G., Carrera, C.G., Mastorino, L., Roccuzzo, G., Dapavo, P., Alberti-Violetti, S., Quaglino, P., and Ribero, S. (2023). Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041662"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjd.18331","article-title":"Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2\u00b75-year results from GESTURE, a randomized, double-blind, placebo-controlled trial","volume":"182","author":"Gottlieb","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_13","first-page":"e15510","article-title":"Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal","volume":"35","author":"Morais","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s13555-021-00606-9","article-title":"Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain","volume":"11","author":"Armesto","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","article-title":"Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study","volume":"81","author":"Torres","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000522008","article-title":"Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A24-Month Real-Life Study","volume":"238","author":"Ortolan","year":"2022","journal-title":"Dermatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1111\/jdv.18087","article-title":"Long-term drug survival of secukinumab in real life in the era of novel biologics: A 5-year, retrospective study, including difficult-to-treat areas","volume":"36","author":"Sotiriou","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s13555-022-00867-y","article-title":"Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study","volume":"13","author":"Nguyen","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ajd.13895","article-title":"Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)","volume":"63","author":"Foley","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1080\/09546634.2020.1854428","article-title":"Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: A 2-year, monocentric, retrospective study","volume":"33","author":"Chatzimichail","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e15081","DOI":"10.1111\/dth.15081","article-title":"A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China","volume":"34","author":"Wang","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Alonso, S., Villa, I., Fern\u00e1ndez, S., Mart\u00edn, J.L., Charca, L., Pino, M., Riancho, L., Morante, I., Santos, M., and Queiro, R. (2021). Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Front. Med., 8.","DOI":"10.3389\/fmed.2021.679009"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1346-8138.15655","article-title":"Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan","volume":"48","author":"Fujita","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: A 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ad.2019.05.018","article-title":"Secukinumab: Drug Survival in Clinical Practice Settings. Secukinumab: Supervivencia en pr\u00e1ctica cl\u00ednica real","volume":"112","year":"2021","journal-title":"Actas Dermosifiliogr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jdv.18329","article-title":"Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: Long-term results from an interim analysis of the SERENA study","volume":"36","author":"Augustin","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/1346-8138.16926","article-title":"Real-world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study (RAILWAY)","volume":"50","author":"Tada","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0300060520964024","article-title":"Impact of smoking on psoriasis risk and treatment efficacy: A meta-analysis","volume":"48","author":"Zhou","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm.-Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: A systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Constantin, M.M., Bucur, S., Mutu, C.C., Poenaru, E., Olteanu, R., Ionescu, R.A., Nicolescu, A.C., Furtunescu, F., and Constantin, T. (2021). The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080752"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Klavdianou, K., Lazarini, A., Grivas, A., Tseronis, D., Tsalapaki, C., Rapsomaniki, P., Antonatou, K., Thomas, K., Boumpas, D., and Vassilopoulos, D. (2020). Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00288"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Orzan, O.A., \u021aieranu, C.G., Olteanu, A.O., Doroban\u021bu, A.M., Cojocaru, A., Mihai, M.M., Popa, L.G., Gheorghiu, A.M., Giurc\u0103neanu, C., and Ion, A. (2023). An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082171"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.31138\/mjr.030124.ntt","article-title":"New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature","volume":"35","author":"Krikelis","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e15067","DOI":"10.1111\/exd.15067","article-title":"Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan","volume":"33","author":"Tada","year":"2024","journal-title":"Exp. Dermatol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/7\/718\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:09:47Z","timestamp":1760108987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/7\/718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jpm14070718"],"URL":"https:\/\/doi.org\/10.3390\/jpm14070718","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}